Present and future rosacea therapy

Cutis

Volumn 75, Issue 3 SUPPL., 2005, Pages 4-7

  Wolf Jr , John E ^a,b,c,d,e,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Managed Care and Professional Affairs   (United States)

^c Bradley Pharmaceuticals Inc   (United States)

^d Doak Dermatologics ^*  (United States)

^e Galderma Laboratories   (United States)

^f Text Mining Services   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CLINDAMYCIN; CLONIDINE; CX 452; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ERYTHROMYCIN; ISOTRETINOIN; MACROLIDE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PEPTIDE; PERMETHRIN; PIMECROLIMUS; RETINOID; SOMATOSTATIN ANALOG; SULFACETAMIDE; SULFUR; TETRACYCLINE DERIVATIVE; TSUKUBAENOLIDE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL RESEARCH; REMISSION; ROSACEA; VALIDATION PROCESS;

ANTI-INFECTIVE AGENTS; BIOMEDICAL RESEARCH; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; FORECASTING; HUMANS; METRONIDAZOLE; ROSACEA; TETRACYCLINE;

EID: 17144375681     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. National Rosacea Society. 14 million Americans have rosacea and most of them don't know it. Available at: http://www.rosacea.org/index.html. Accessed August 25, 2004.
2. Del Rosso JQ. Shining new light on rosacea: perspectives on pathogenesis, trigger factors, and therapy. Skin Aging. 2003;(suppl):3-7.
3. Kligman AM. A personal critique on the state of knowledge of rosacea. Dermatology. 2004;208:191-197.
4. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
5. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
6. Oztas MO, Balk M, Ogus E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192.
7. Powell FC. What's going on in rosacea? J Eur Acad Dermatol Venereol. 2000;14:351-352.
8. Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50:266-272.
9. Marks R. Is early rosacea distinguishable from the effects of weathering on facial skin? J Am Acad Dermatol. 2004;50(suppl):19. Abstract P76.
10. Marks R. Histogenesis of the inflammatory component of rosacea. Proc R Soc Med. 1973;66:742-745.
11. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol. 1998;37:263-266.
12. National Rosacea Society. Research grants program. Available at: http://www.rosacea.org/grants/awards.html. Accessed August 25, 2004.
13. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-587.
14. Wilkin J, Dahl M, Detmar M, et al, for the National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
15. Bamford JTM, Elliot BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-108.
16. Slawson D. Permethrin cream useful in the treatment of rosacea. Am Fam Physician. 2003;67:1782-1783.
17. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73(suppl 6):11-17.
18. Fuller BB, Smith D, Pilcher B, et al. Clinical efficacy of a novel non-steroidal anti-inflammatory molecule in treating the symptoms of rosacea. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. P146.
19. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
20. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;74(suppl 3):21-27.
21. Pierard-Franchimont C, Quatresooz P, Pierard GE. Incidental control of rosacea by somatostatin. Dermatology. 2003;206:249-251.
22. Lowe NJ, Behr KL, Fitzpatrick R, et al. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol. 1991;17:522-525.
23. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci. 2002;17:26-33.
24. Taub AF. Photodynamic therapy in dermatology: history and horizons. J Drugs Dermatol. 2004;3(suppl 1):S8-S25.
25. Goldberg DJ. Lasers and light sources for rosacea. Cutis. 2005;75(suppl 3):22-26.
26. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
27. van Zuuren EJ, Graber MA, Hollis S, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2004;1:CD003262.
28. van Zuuren EJ, Graber MA. The rigor of trials evaluating rosacea treatments. Cutis. 2005;75(suppl 3):13-16.